Update on the pharmacogenetics of NATs: Structural considerations

Pharmacogenomics

Volumn 9, Issue 11, 2008, Pages 1673-1693

  Stanley, Lesley A ^a   Sim, Edith ^b  

^a Consultant in Investigative Toxicology ^*  (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

acetylation; alternative splicing; arylamine N acetyltransferase; catalytic triad; geneenvironment interactions; isoniazid; noncoding exons; polymorphism; proteasomal degradation; protein structure

Indexed keywords

ACYLTRANSFERASE; AMONAFIDE; AROMATIC AMINE; HETEROCYCLIC AMINE; HYDRAZINE; TAMOXIFEN; ARYLAMINE ACETYLTRANSFERASE;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CARCINOGENESIS; CATALYSIS; CELL METABOLISM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME POLYMORPHISM; ENZYME STRUCTURE; ETHNIC DIFFERENCE; GENE EXPRESSION REGULATION; GENE STRUCTURE; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HOMEOSTASIS; HORMONE RESPONSE; HUMAN; NEURAL TUBE DEFECT; NONHUMAN; PHARMACOGENETICS; PHENOTYPE; POPULATION GENETICS; PROSTATE CANCER; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN METABOLISM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; GENETIC POLYMORPHISM; GENETICS; METABOLISM;

ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETICS, POPULATION; HUMANS; MODELS, MOLECULAR; NEURAL TUBE DEFECTS; POLYMORPHISM, GENETIC; PROTEIN FOLDING;

EID: 61549138129     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.11.1673     Document Type: Review

References (120)

1. Hein DW: Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat. Res. 506-507, 65-77 (2002).
2. Butcher NJ, Boukouvala S, Sim E, Minchin RF: Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J. 2, 30-42 (2002). (Pubitemid 34982201)
3. Westwood IM, Kawamura A, Fullam E, Russell AJ, Davies SG, Sim E: Structure and mechanism of arylamine N-acetyltransferases. Curr. Top. Med. Chem. 6, 1641-1654 (2006). (Pubitemid 44304619)
4. Westwood IM, Holton SJ, Rodrigues-Lima F, et al. Expression, purification, characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferase. Biochem. J. 385, 605-612 (2005). (Pubitemid 40165095)
5. Sim E, Westwood I, Fullam E: Arylamine N-acetyltransferases. Expert Opin. Drug Metab. Toxicol. 3, 169-184 (2007). (Pubitemid 47316039)
6. Minchin RF, Hanna PE, Dupret JM, Wagner CR, Rodrigues-Lima F, Butcher NJ: Arylamine N-acetyltransferase I. Int. J. Biochem. Cell Biol. 39, 1999-2005 (2007). (Pubitemid 47369238)
7. Boukouvala S, Fakis G: Arylamine N-acetyltransferases: what we learn from genes and genomes. Drug Metab. Rev. 37, 511-564 (2005). (Pubitemid 41434161)
8. Hein DW, Boukouvala S, Grant DM, Minchin RF, Sim E: Changes in consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenet. Genomics 18, 367-368 (2008). (Pubitemid 351367530)
9. Hein DW, Doll MA, Fretland AJ, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomarkers Prev. 9, 29-42 (2000).
10. Boukouvala S, Sim E: Structural analysis of the genes for human arylamine N-acetyltransferases and characterisation of alternative transcripts. Basic Clin. Pharmacol. Toxicol. 96, 343-351 (2005). (Pubitemid 40676587)
11. Zhu Y, Hein DW, Doll MA, et al. Simultaneous determination of 7 N-acetyltransferase-2 single-nucleotide variations by allele-specific primer extension assay. Clin. Chem. 52, 1033-1039 (2006). (Pubitemid 43794414)
12. Doll MA, Hein DW: Comprehensive human NAT2 genotype method using single nucleotide polymorphism-specific polymerase chain reaction primers and fluorogenic probes. Anal. Biochem. 288, 106-108 (2001).
13. Doll MA, Hein DW: Rapid genotype method to distinguish frequent and/or functional polymorphisms in human N-acetyltransferase-1. Anal. Biochem. 301, 328-332 (2002).
14. Yuliwulandari R, Sachrowardi Q, Nishida N, et al. Polymorphisms of promoter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature. J. Hum. Genet. 53, 201-209 (2008).
15. Zhangwei X, Jianming X, Qiao M, Xinhua X: N-acetyltransferase-1 gene polymorphisms and correlation between genotype and its activity in a central Chinese Han population. Clin. Chim. Acta. 371, 85-91 (2006). (Pubitemid 44177578)
16. Goodfellow GH, Dupret JM, Grant DM: Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2. Biochem. J. 348 (Pt 1), 159-166 (2000).
17. Sinclair JC, Sandy J, Delgoda R, Sim E, Noble ME: Structure of arylamine N-acetyltransferase reveals a catalytic triad. Nat. Struct. Biol. 7, 560-564 (2000). (Pubitemid 30445912)
18. Zhang N, Liu L, Liu F, Wagner CR, Hanna PE, Walters KJ: NMR-based model reveals the structural determinants of mammalian arylamine N-acetyltransferase substrate specificity. J. Mol. Biol. 363, 188-200 (2006). (Pubitemid 44414850)
19. Wu H, Dombrovsky L, Tempel W, et al. Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases. J. Biol. Chem. 282, 30189-30197 (2007). (Pubitemid 350035257)
20. Kawamura A, Graham J, Mushtaq A, et al. Eukaryotic arylamine N-acetyltransferase. Investigation of substrate specificity by high-throughput screening. Biochem. Pharmacol. 69, 347-359 (2005). (Pubitemid 41556581)
21. Cornish VA, Pinter K, Boukouvala S, et al. Generation and analysis of mice with a targeted disruption of the arylamine N-acetyltransferase type 2 gene. Pharmacogenomics J. 3, 169-177 (2003). (Pubitemid 36850158)
22. Stanley LA, Copp AJ, Pope J, et al. Immunochemical detection of arylamine N-acetyltransferase during mouse embryonic development and in adult mouse brain. Teratology 58, 174-182 (1998). (Pubitemid 28542486)
23. Jensen LE, Hoess K, Mitchell LE, Whitehead AS: Loss of function polymorphisms in NAT1 protect against spina bifida. Hum. Genet. 120, 52-57 (2006).
24. Jensen LE, Hoess K, Whitehead AS, Mitchell LE: The NAT1 C1095A polymorphism, maternal multivitamin use and smoking, and the risk of spina bifida. Birth Defects Res. A Clin. Mol. Teratol. 73, 512-516 (2005). (Pubitemid 41045299)
25. Sim E, Walters K, Boukouvala S: Arylamine N-acetyltransferases: from structure to function. Drug Metab. Rev. 40, 479-510 (2008). (Pubitemid 352019961)
26. Sim E, Sandy J, Evangelopoulos D, et al. Arylamine N-acetyltransferases in mycobacteria. Curr. Drug Metab. 9, 510-519 (2008). (Pubitemid 352025182)
27. Agundez JA: Polymorphisms of human N-acetyltransferases and cancer risk. Curr. Drug Metab. 9, 520-531 (2008). (Pubitemid 352025183)
28. Butcher NJ, Tiang J, Minchin RF: Regulation of arylamine N-acetyltransferases. Curr. Drug Metab. 9, 498-504 (2008). (Pubitemid 352025180)
29. Agundez JA: N-acetyltransferases: lessons learned from eighty years of research. Curr. Drug Metab. 9, 463-464 (2008). (Pubitemid 352025177)
30. Grant DM: Structures of human arylamine N-acetyltransferases. Curr. Drug Metab. 9, 465-470 (2008).
31. Fakis G, Boukouvala S, Buckle V, Payton M, Denning C, Sim E: Chromosome mapping of the genes for murine arylamine N-acetyltransferases (NATs), enzymes involved in the metabolism of carcinogens: identification of a novel upstream noncoding exon for murine Nat2. Cytogenet. Cell Genet. 90, 134-138 (2000).
32. Boukouvala S, Price N, Plant KE, Sim E: Structure and transcriptional regulation of the Nat2 gene encoding for the drugmetabolizing enzyme arylamine N-acetyltransferase type 2 in mice. Biochem. J. 375, 593-602 (2003). (Pubitemid 37433507)
33. Butcher NJ, Arulpragasam A, Goh HL, Davey T, Minchin RF: Genomic organization of human arylamine N-acetyltransferase Type I reveals alternative promoters that generate different 5β-UTR splice variants with altered translational activities. Biochem. J. 387, 119-127 (2005). (Pubitemid 40524081)
34. Butcher NJ, Arulpragasam A, Pope C, Minchin RF: Identification of a minimal promoter sequence for the human N-acetyltransferase type I gene that binds AP-1 (activator protein 1) and YY-1 (Yin and Yang 1). Biochem. J. 376, 441-448 (2003). (Pubitemid 38010529)
35. Husain A, Barker DF, States JC, Doll MA, Hein DW: Identification of the major promoter and non-coding exons of the human arylamine N-acetyltransferase 1 gene (NAT1). Pharmacogenetics 14, 397-406 (2004). (Pubitemid 38971230)
36. Husain A, Zhang X, Doll MA, States JC, Barker DF, Hein DW: Functional analysis of the human N-acetyltransferase 1 major promoter: quantitation of tissue expression and identification of critical sequence elements. Drug Metab. Dispos. 35, 1649-1656 (2007). (Pubitemid 47296060)
37. Barker DF, Husain A, Neale JR, et al. Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1. Pharmacogenet. Genomics 16, 515-525 (2006). (Pubitemid 43922348)
38. Husain A, Zhang X, Doll MA, States JC, Barker DF, Hein DW: Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues. Drug Metab. Dispos. 35, 721-727 (2007). (Pubitemid 46641541)
39. Mitchell KR, Warshawsky D: Xenobiotic inducible regions of the human arylamine N-acetyltransferase 1 and 2 genes. Toxicol. Lett. 139, 11-23 (2003). (Pubitemid 36197843)
40. Kim SJ, Kang HS, Chang HL, et al. Promoter hypomethylation of the N-acetyltransferase 1 gene in breast cancer. Oncol. Rep. 19, 663-668 (2008). (Pubitemid 351330433)
41. Adam PJ, Berry J, Loader JA, et al. Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol. Cancer Res. 1, 826-835 (2003). (Pubitemid 37174454)
42. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
43. Simard E, Naud J, Michaud J, et al. Downregulation of hepatic acetylation of drugs in chronic renal failure. J. Am. Soc. Nephrol. 19, 1352-1359 (2008).
44. Sandy J, Mushtaq A, Kawamura A, Sinclair J, Sim E, Noble M: The structure of arylamine N-acetyltransferase from Mycobacterium smegmatis -an enzyme which inactivates the anti-tubercular drug, isoniazid. J. Mol. Biol. 318, 1071-1083 (2002). (Pubitemid 35007369)
45. Sandy J, Mushtaq A, Holton SJ, Schartau P, Noble ME, Sim E: Investigation of the catalytic triad of arylamine N-acetyltransferases: essential residues required for acetyl transfer to arylamines. Biochem. J. 390, 115-123 (2005). (Pubitemid 41192237)
46. Mushtaq A, Payton M, Sim E: The COOH terminus of arylamine N-acetyltransferase from Salmonella typhimurium controls enzymic activity. J. Biol. Chem. 277, 12175-12181 (2002). (Pubitemid 34952783)
47. Fullam E, Westwood IM, Anderton MC, Lowe ED, Sim E, Noble ME: Divergence of cofactor recognition across evolution: coenzyme A binding in a prokaryotic arylamine N-acetyltransferase. J. Mol. Biol. 375, 178-191 (2008). (Pubitemid 350160690)
48. Delgoda R, Lian LY, Sandy J, Sim E: NMR investigation of the catalytic mechanism of arylamine N-acetyltransferase from Salmonella typhimurium. Biochim. Biophys. Acta. 1620, 8-14 (2003). (Pubitemid 36197891)
49. Sim E, Pinter K, Mushtaq A, et al. Arylamine N-acetyltransferases: a pharmacogenomic approach to drug metabolism and endogenous function. Biochem. Soc. Trans. 31, 615-619 (2003). (Pubitemid 36750741)
50. Payton M, Mushtaq A, Yu TW, Wu LJ, Sinclair J, Sim E: Eubacterial arylamine N-acetyltransferases -identification and comparison of 18 members of the protein family with conserved active site cysteine, histidine and aspartate residues. Microbiology 147, 1137-1147 (2001). (Pubitemid 32454632)
51. Walraven JM, Trent JO, Hein DW: Computational and experimental analyses of mammalian arylamine N-acetyltransferase structure and function. Drug Metab. Dispos. 35, 1001-1007 (2007).
52. Walraven JM, Trent JO, Hein DW: Structurefunction analyses of single nucleotide polymorphisms in human N-acetyltransferase 1. Drug Metab. Rev. 40, 169-184 (2008). (Pubitemid 351220644)
53. Zang Y, Zhao S, Doll MA, States JC, Hein DW: The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation. Pharmacogenetics 14, 717-723 (2004). (Pubitemid 39552786)
54. Zang Y, Doll MA, Zhao S, States JC, Hein DW: Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis 28, 1665-1671 (2007). (Pubitemid 47289027)
55. Zang Y, Zhao S, Doll MA, Christopher States J, Hein DW: Functional characterization of the A411T (L137F) and G364A (D122N) genetic polymorphisms in human N-acetyltransferase 2. Pharmacogenet. Genomics 17, 37-45 (2007). (Pubitemid 46183790)
56. Zhu Y, Hein DW: Functional effects of single nucleotide polymorphisms in the coding region of human N-acetyltransferase 1. Pharmagenomics J. 8(5), 339-348 (2007).
57. Liu F, Zhang N, Zhou X, et al. Arylamine N-acetyltransferase aggregation and constitutive ubiquitylation. J. Mol. Biol. 361, 482-492 (2006). (Pubitemid 44118334)
58. Butcher NJ, Arulpragasam A, Minchin RF: Proteasomal degradation of N-acetyltransferase 1 is prevented by acetylation of the active site cysteine: a mechanism for the slow acetylator phenotype and substrate-dependent down-regulation. J. Biol. Chem. 279, 22131-22137 (2004). (Pubitemid 38679406)
59. Martell KJ, Levy GN, Weber WW: Cloned mouse N-acetyltransferases: enzymatic properties of expressed Nat-1 and Nat-2 gene products. Mol. Pharmacol. 42, 265-272 (1992).
60. Boukouvala S, Price N, Sim E: Identification and functional characterization of novel polymorphisms associated with the genes for arylamine N-acetyltransferases in mice. Pharmacogenetics 12, 385-394 (2002). (Pubitemid 34816418)
61. Patin E, Barreiro LB, Sabeti PC, et al. Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes. Am. J. Hum. Genet. 78, 423-436 (2006). (Pubitemid 43291225)
62. Magalon H, Patin E, Austerlitz F, et al. Population genetic diversity of the NAT2 gene supports a role of acetylation in human adaptation to farming in Central Asia. Eur. J. Hum. Genet. 16, 243-251 (2008).
63. Patin E, Harmant C, Kidd KK, et al. Sub-Saharan African coding sequence variation and haplotype diversity at the NAT2 gene. Hum. Mutat. 27, 720 (2006).
64. Sabbagh A, Langaney A, Darlu P, Gerard N, Krishnamoorthy R, Poloni ES: Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet. 9, 21 (2008). (Pubitemid 351552575)
65. Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 449, 851-861 (2007).
66. Spielberg SP: N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J. Pharmacokinet. Biopharm. 24, 509-519 (1996).
67. Cartwright RA, Glashan RW, Rogers HJ, et al. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 2, 842-845 (1982).
68. Lower Jr GM, Nilsson T, Nelson CE, Wolf H, Gamsky TE, Bryan GT: N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ. Health Perspect. 29, 71-79 (1979). (Pubitemid 9190956)
69. Risch A, Wallace DM, Bathers S, Sim E: Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum. Mol. Genet. 4, 231-236 (1995).
70. Garcia-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366, 649-659 (2005) (Pubitemid 41176017)
71. Lubin JH, Kogevinas M, Silverman D, et al. Evidence for an intensity-dependent interaction of NAT2 acetylation genotype and cigarette smoking in the Spanish Bladder Cancer Study. Int. J. Epidemiol. 36, 236-241 (2007). (Pubitemid 47061604)
72. Murta-Nascimento C, Silverman DT, Kogevinas M, et al. Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk? Cancer Epidemiol. Biomarkers Prev. 16, 1595-1600 (2007). (Pubitemid 47294824)
73. Rothman N, Garcia-Closas M, Hein DW: Commentary: Reflections on G. M. Lower and colleagues 1979 study associating slow acetylator phenotype with urinary bladder cancer: meta-analysis, historical refinements of the hypothesis, and lessons learned. Int. J. Epidemiol. 36, 23-28 (2007). (Pubitemid 47064257)
74. Carreon T, Ruder AM, Schulte PA, et al. NAT2 slow acetylation and bladder cancer in workers exposed to benzidine. Int. J. Cancer 118, 161-168 (2006). (Pubitemid 41681593)
75. Hein DW: N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 25, 1649-1658 (2006).
76. Rothman N, Bhatnagar VK, Hayes RB, et al. The impact of interindividual variation in NAT2 activity on benzidine urinary metabolites and urothelial DNA adducts in exposed workers. Proc. Natl. Acad. Sci. USA 93, 5084-5089 (1996). (Pubitemid 26162874)
77. Zhang X, Lambert JC, Doll MA, Walraven JM, Arteel GE, Hein DW: 4,4′-methylenedianiline-induced hepatotoxicity is modified by N-acetyltransferase 2 (NAT2) acetylator polymorphism in the rat. J. Pharmacol. Exp. Ther. 316, 289-294 (2006). (Pubitemid 41832608)
78. Butler LM, Millikan RC, Sinha R, et al. Modification by N-acetyltransferase 1 genotype on the association between dietary heterocyclic amines and colon cancer in a multiethnic study. Mutat. Res. 638, 162-174 (2008).
79. Mahid SS, Colliver DW, Crawford NP, et al. Characterization of N-acetyltransferase 1 and polymorphisms and haplotype analysis for inflammatory bowel disease and sporadic colorectal carcinoma. BMC Med. Genet. 8, 28 (2007).
80. Olden K: Commentary: from phenotype, to genotype, to gene-environment interaction and risk for complex diseases. Int. J. Epidemiol. 36, 18-20 (2007). (Pubitemid 47064255)
81. Sanderson S, Salanti G, Higgins J: Joint effects of the N-acetyltransferase 1 and 2 (NAT1 and NAT2) genes and smoking on bladder carcinogenesis: a literature-based systematic HuGE review and evidence synthesis. Am. J. Epidemiol. 166, 741-751 (2007). (Pubitemid 47428907)
82. Wilke RA, Reif DM, Moore JH: Combinatorial pharmacogenetics. Nat. Rev. Drug Discov. 4, 911-918 (2005).
83. Jiao L, Doll MA, Hein DW, et al. Haplotype of N-acetyltransferase 1 and 2 and risk of pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 16, 2379-2386 (2007). (Pubitemid 351196371)
84. Li D, Jiao L, Li Y, et al. Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis 27, 103-111 (2006). (Pubitemid 43025249)
85. Alberg AJ, Daudt A, Huang HY, et al. N-acetyltransferase 2 (NAT2) genotypes, cigarette smoking, and the risk of breast cancer. Cancer Detect. Prev. 28, 187-193 (2004). (Pubitemid 38836826)
86. Lissowska J, Brinton LA, Zatonski W, et al. Tobacco smoking, NAT2 acetylation genotype and breast cancer risk. Int. J. Cancer 119, 1961-1969 (2006). (Pubitemid 44356858)
87. Terry PD, Goodman M: Is the association between cigarette smoking and breast cancer modified by genotype? A review of epidemiologic studies and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 15, 602-611 (2006).
88. Ochs-Balcom HM, Wiesner G, Elston RC: A meta-analysis of the association of N-acetyltransferase 2 gene (NAT2) variants with breast cancer. Am. J. Epidemiol. 166, 246-254 (2007). (Pubitemid 47216806)
89. Ambrosone CB, Kropp S, Yang J, Yao S, Shields PG, Chang-Claude J: Cigarette smoking, N-acetyltransferase 2 genotypes, and breast cancer risk: pooled analysis and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 17, 15-26 (2008). (Pubitemid 351196269)
90. Egeberg R, Olsen A, Autrup H, et al. Meat consumption, N-acetyl transferase 1 and 2 polymorphism and risk of breast cancer in Danish postmenopausal women. Eur. J. Cancer Prev. 17, 39-47 (2008). (Pubitemid 350307516)
91. Bieche I, Girault I, Urbain E, Tozlu S, Lidereau R: Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor a-positive postmenopausal breast carcinoma. Breast Cancer Res. 6, R252-R263 (2004).
92. Ring BZ, Seitz RS, Beck R, et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J. Clin. Oncol. 24, 3039-3047 (2006). (Pubitemid 46638938)
93. Dolled-Filhart M, Ryden L, Cregger M, et al. Classification of breast cancer using genetic algorithms and tissue microarrays. Clin. Cancer Res. 12, 6459-6468 (2006). (Pubitemid 44799719)
94. Wakefield L, Robinson J, Long H, et al. Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: a potential marker in estrogen receptor-positive tumors. Genes Chromosomes Cancer 47, 118-126 (2008).
95. Kawamura A, Westwood I, Wakefield L, et al. Mouse N-acetyltransferase type 2, the homologue of human N-acetyltransferase type 1. Biochem. Pharmacol. 75, 1550-1560 (2008).
96. Ragunathan N, Dairou J, Pluvinage B, et al. Identification of the xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 as a new target of cisplatin in breast cancer cells: molecular and cellular mechanisms of inhibition. Mol. Pharmacol. 73, 1761-1768 (2008). (Pubitemid 351724363)
97. Butcher NJ, Tetlow NL, Cheung C, Broadhurst GM, Minchin RF: Induction of human arylamine N-acetyltransferase Type I by androgens in human prostate cancer cells. Cancer Res. 67, 85-92 (2007). (Pubitemid 46142762)
98. Norton JT, Witschi MA, Luong L, et al. Synthesis and anticancer activities of 6-amino amonafide derivatives. Anticancer Drugs 19, 23-36 (2008). (Pubitemid 350190965)
99. Smelt VA, Upton A, Adjaye J, et al. Expression of arylamine N-acetyltransferases in pre-term placentas and in human pre-implantation embryos. Hum. Mol. Genet. 9, 1101-1107 (2000). (Pubitemid 30216016)
100. Wakefield L, Long H, Lack N, Sim E: Ocular defects associated with a null mutation in the mouse arylamine N-acetyltransferase 2 gene. Mamm. Genome 18, 270-276 (2007). (Pubitemid 46897403)
101. Sugamori KS, Wong S, Gaedigk A, et al. Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice. Mol. Pharmacol. 64, 170-179 (2003). (Pubitemid 36759829)
102. Sugamori KS, Brenneman D, Wong S, et al. Effect of arylamine acetyltransferase Nat3 gene knockout on N-acetylation in the mouse. Drug Metab. Dispos. 35, 1064-1070 (2007). (Pubitemid 46956425)
103. Wakefield L, Cornish V, Broackes-Carter F, Sim E: Arylamine N-acetyltransferase 2 expression in the developing heart. J. Histochem. Cytochem. 53, 583-592 (2005). (Pubitemid 40593971)
104. Wakefield L, Cornish V, Long H, et al. Mouse arylamine N-acetyltransferase 2 (Nat2) expression during embryogenesis: a potential marker for the developing neuroendocrine system. Biomarkers 13, 106-118 (2008).
105. Cao W, Chau B, Hunter R, Strnatka D, McQueen CA, Erickson RP: Only low levels of exogenous N-acetyltransferase can be achieved in transgenic mice. Pharmacogenomics J. 5, 255-261 (2005). (Pubitemid 41131717)
106. Wakefield L, Cornish V, Long H, Griffiths WJ, Sim E: Deletion of a xenobiotic metabolizing gene in mice affects folate metabolism. Biochem. Biophys. Res. Commun. 364, 556-560 (2007). (Pubitemid 350030921)
107. Erickson RP, Cao W, Acuna DK, et al. Confirmation of the role of N-acetyltransferase 2 in teratogen-induced cleft palate using transgenics and knockouts. Mol. Reprod. Dev. 75, 1071-1076 (2008). (Pubitemid 351628592)
108. Lammer EJ, Shaw GM, Iovannisci DM, Finnell RH: Periconceptional multivitamin intake during early pregnancy, genetic variation of acetyl-N-transferase 1 (NAT1), and risk for orofacial clefts. Birth Defects Res. A Clin. Mol. Teratol. 70, 846-852 (2004).
109. Lammer EJ, Shaw GM, Iovannisci DM, Finnell RH: Maternal smoking, genetic variation of glutathione S-transferases, and risk for orofacial clefts. Epidemiology 16, 698-701 (2005).
110. Carmichael SL, Shaw GM, Yang W, Iovannisci DM, Lammer E: Risk of limb deficiency defects associated with NAT1, NAT2, GSTT1, GSTM1, and NOS3 genetic variants, maternal smoking, and vitamin supplement intake. Am. J. Med. Genet. A. 140, 1915-1922 (2006).
111. Shi M, Christensen K, Weinberg CR, et al. Orofacial cleft risk is increased with maternal smoking and specific detoxification-gene variants. Am. J. Hum. Genet. 80, 76-90 (2007). (Pubitemid 46047652)
112. Stanislawska-Sachadyn A, Jensen LE, Kealey C, et al. Association between the NAT1 1095C > A polymorphism and homocysteine concentration. Am J. Med. Genet. A. 140, 2374-2377 (2006). (Pubitemid 44684968)
113. Sim E, Payton M, Noble M, Minchin R: An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eucaryotes and procaryotes. Hum. Mol. Genet. 9, 2435-2441 (2000).
114. Pluvinage B, de la Sierra-Gallay IL, Martins M, Ragunathan N, Dupret JM, Rodrigues-Lima F: Crystallization and preliminary x-ray characterization of arylamine N-acetyltransferase C (BanatC) from Bacillus anthracis. Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun. 63, 862-864 (2007). (Pubitemid 47511901)
115. Pluvinage B, Dairou J, Possot OM, et al. Cloning and molecular characterization of three arylamine N-acetyltransferase genes from Bacillus anthracis: identification of unusual enzymatic properties and their contribution to sulfamethoxazole resistance. Biochemistry 46, 7069-7078 (2007). (Pubitemid 46906436)
116. Brooke EW, Davies SG, Mulvaney AW, et al. Synthesis and in vitro evaluation of novel small molecule inhibitors of bacterial arylamine N-acetyltransferases (NATs). Bioorg. Med. Chem. Lett. 13, 2527-2530 (2003).
117. Bhakta S, Besra GS, Upton AM, et al. Arylamine N-acetyltransferase is required for synthesis of mycolic acids and complex lipids in Mycobacterium bovis BCG and represents a novel drug target. J. Exp. Med. 199, 1191-1199 (2004). (Pubitemid 38620256)
118. Hein DW, Doll MA, Fretland AJ, et al. Rodent models of the human acetylation polymorphism: comparisons of recombinant acetyltransferases. Mutat. Res. 376, 101-106 (1997).
119. Walraven JM, Barker DF, Doll MA, Hein DW: Tissue expression and genomic sequences of rat N-acetyltransferases rNat1, rNat2, rNat3, and functional characterization of a novel rNat32 genetic variant. Toxicol. Sci. 99, 413-421 (2007).
120. Nat website http://louisville.edu/medschool/pharmacology/NAT.html